Given the enormous impact of BCR-ABL in causing CML, the treatment of this disease has shifted from conventional therapy to targeting this fused tyrosine kinase, such as the significant clinical breakthroughs achieved with imatinib [4]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.